|
 |
 |
 |
|||
 |
 |
 |
 |
 |
 |
 |
Co-ChairsLeonard G. Gomella, MD Leonard Gomella, MD, is the Bernard W. Godwin Professor of Prostate Cancer and Chairman of the Department of Urology at Jefferson Kimmel Cancer Center Thomas Jefferson University. Originally from New York, Dr. Gomella completed medical school, general surgery, and urology training at the University of Kentucky in Lexington, Kentucky. After a Urologic Oncology Fellowship in the Surgery Branch of the National Cancer Institute in Bethesda, Maryland, he joined the faculty of Jefferson Medical College in 1988 and was appointed Chair in 2002. He is also Associate Director of Clinical Affairs for the Jefferson Kimmel Cancer and Urology Chair for RTOG, serving as lead Urology Investigator on multiple national trials. In 2008 he was named Clinical Director of the Jefferson Kimmel Cancer Center Network. Dr. Gomella is involved in both basic science and clinical research in the development of new diagnostic techniques and treatments for prostate, bladder, and kidney cancer through Jefferson’s Kimmel Cancer Center. Dr. Gomella’s team was first to use RT-PCR to detect micrometastasis in patients with prostate cancer, a discovery that led to a new field of investigation in this disease. Dr. Gomella is also recognized as an early contributor to urologic laparoscopy, initiating the program at Jefferson in 1990. He has given almost 500 presentations at local, national, and international meetings and written over 300 papers, chapters, and monographs in the field of urology. Journal appointments have included serving on the Editorial Board of the Investigative Section of the Journal of Urology, as Co-Editor-in-Chief of Techniques in Urology, and on the boards of several journals including Urologic Oncology, Clinical Genitourinary Cancer, and American Journal of Pathology. He is a consultant to two dozen journals in the field of urology and oncology and in 2010 was appointed Editor-in-Chief of the Canadian Journal of Urology. Dr. Gomella has authored and edited 54 editions of 17 different books for medical students, residents, and practicing physicians, many of which have been translated into foreign languages. He is the Editor-in-Chief of the “5 Minute Urology Consult,” and laparoscopy section editor for Glenn’s Urologic Surgery. Recovering from Prostate Cancer, the first book for the public dedicated to this topic, was authored by Dr. Gomella. In the field of medicine, Dr. Gomella is known for the Clinician’s Pocket Reference, now in its 11th edition, a widely used reference for medical students and health care providers. Best Doctors in America, Top Doctors for Cancer, and Philadelphia Magazine’s Top Doctors have recognized him for many years for urologic oncology and prostate cancer. In 2007, Men’s Health Magazine listed Dr. Gomella as one of the 20 top urologists in the US. Awards received have included the American Cancer Society Volunteer Achievement Award and a National Cancer Institute Achievement Award. He has served as President of the Mid-Atlantic Section of the American Urological Association and was elected to membership in the American Association of Genitourinary Surgeons in 2008. The University of Kentucky College of Medicine awarded him a Distinguished Alumnus Award For Academic Excellence in 2009. Disclosures |
|
 |
Daniel P. Petrylak, MD Daniel P. Petrylak, MD, completed his medical degree at Case Western Reserve University School of Medicine, and completed his internal medicine residency at Albert Einstein College of Medicine/Jacobi Medical Center and fellowship at Memorial Sloan-Kettering Cancer Center. Since 1995, Dr. Petrylak is a Professor of Medicine in the Division of Medical Oncology at Columbia University Medical Center and Program Director of the Genitourinary Oncology Section in the Division of Medical Oncology. He is also the Co-Director of the Prostate Cancer Program in the Herbert Irving Cancer Center. Since appointed Program Director in 1995, Dr. Petrylak focused the section on the development of novel therapeutic agents for the treatment of prostate cancer. The first phase I study of docetaxel combined with estramustine was performed by Dr. Petrylak in the Herbert Irving General Clinical Research Center. Dr. Petrylak is involved in clinical trials research on a local, national, and international level. He is the Head of the Advanced Bladder Subcommittee in the Southwest Oncology Group Genitourinary Committee. Dr. Petrylak served as Principal Investigator or Co-Principal Investigator on seven Southwest Oncology Group Protocols. Most notably, he served as the Principal Investigator for a randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone in men with hormone refractory prostate cancer. This trial was one of two studies that demonstrated a survival benefit for docetaxel-based therapy in men with advanced prostate cancer. This trial supported the approval of docetaxel for hormone refractory prostate cancer by the FDA. He also helped to design and served as Principal Investigator for the SPARC trial, an international registration trial evaluating the activity of satraplatin as a second-line therapy for hormone refractory prostate cancer. He was also one of the Principal Investigators on the SPARC study, which evaluated satraplatin as second-line therapy for endocrine-resistant prostate cancer. Dr. Petrylak is a recognized international leader in the field. He has served on the program committee for the annual meetings of the American Urological Association (2003-7) as well as for the American Society of Clinical Oncology (1995-7, 2001-3). He also has served as a committee member for the Devices and Immunological Section of the FDA. He has published extensively in the New England Journal of Medicine, Journal of Clinical Oncology, Journal of the National Cancer Institute, as well as Cancer Research and Clinical Cancer Research. Disclosures |
|
 |
FacultyE. Roy Berger, MD E. Roy Berger, MD, is a medical oncologist with over 30 years of experience in the diagnosis and treatment of solid tumors, hematologic malignancies, and supportive care. After earning his medical degree from SUNY Downstate Medical Center College of Medicine, Dr. Berger trained at Columbia College of Physicians and Surgeons and Memorial Sloan-Kettering Cancer Center. He is board certified in both oncology and hematology. He serves on the faculty at SUNY at Stony Brook as an Assistant Clinical Professor and has been a Clinical Affiliate and Consultant at Memorial Sloan-Kettering Cancer Center. He was one of the founders of North Shore Hematology/Oncology Associates, one of the most recognized and prestigious practices in the US. He has extensive clinical experience as a principal investigator in clinical trials. In addition, he was an investigator in the trials that led to the FDA approval of strontium and flutamide. Community outreach and patient advocacy have always been an important part of Dr. Berger’s professional career. He is a founding member of the Prostate Cancer Education Council, a group that sponsors free prostate cancer screenings nationally. In addition, he serves on the medical advisory boards of two of the largest patient advocacy groups in the US for patients with prostate cancer. His numerous appearances on television and radio have made him an important voice in the medical media. Dr. Berger was cited in Guide to America’s Top Physicians, How to Find the Best Doctor for Your Family (Castle Connolly), and Top Doctors in the New York Metro Area (Castle Connolly). Dr. Berger is widely published, having authored over 150 articles, clinical communications, reviews, and editorials and written 3 books. His book Common Bonds, Reflections of a Cancer Doctor was critically acclaimed as a fresh look at the oncologist/patient relationship. His professional consultancy experience includes participation on multiple pharmaceutical and national speaker advisory boards. He also provides consulting services to insurance companies, financial institutions, biotechnology firms, and pharmaceutical companies. He is a member of both the American Society of Clinical Oncology and the American Society of Hematology. He serves on the editorial board of Oncology Net Guide and is the Physician Editor of Oncology & Biotech News and Contemporary Oncology. In addition to his many accomplishments, Dr. Berger has been elected to the Strathmore Professional Honor Society. Dr. Berger joined TRM Oncology, a global strategic medical communications agency that limits its projects to medical oncology, hematology, and supportive care. He served as Medical Director from January 2009 to January 2010. He was in charge of all medical information that was related to seminars, advisory boards, and publications. Disclosures |
|
 |
E. David Crawford, MD E. David Crawford, MD, is a Professor of Surgery, Urology, and Radiation Oncology and Head of Urologic Oncology in the Urologic Oncology Department at the University of Colorado Denver in Aurora, Colorado. He also serves as Associate Director of the University of Colorado Cancer Center in Denver. Dr. Crawford earned his medical degree from the University of Cincinnati in Ohio. He completed his residency in the Department of Surgery at Good Samaritan Hospital in Cincinnati, followed by a clinical fellowship in urology at the University of California Medical Center in Los Angeles. He is a fellow of the American College of Surgeons and board certified by the American Board of Urology. Considered a “legend in urology” by the Canadian Journal of Urology, Dr. Crawford has been the recipient of numerous research grants and has participated in several Southwest Oncology Group and National Cancer Institute protocols. In addition to his tenure of Chair of the Genitourinary Committee for the Southwest Oncology Group for 28 years and current Chair of the National Prostate Cancer Education Council, Dr. Crawford is a member of the Prostate Cancer Trialists’ Collaborative Group and the Alliance for Prostate Cancer Prevention. He is a founding member of the Society of Urologic Oncology and a member of many other professional organizations, including the American Fertility Society, American Urological Association, American Society of Clinical Oncology, Association for Academic Surgery, European Academy of Sciences, Société Internationale d’Urologie, International Society of Cancer Chemoprevention, and European Association of Urology, among others. Dr. Crawford is currently a Consulting Editor for Prostate Cancer and Prostatic Diseases and Editor for Urology Grand Rounds, as well as an Editorial Board Member for Oncology, Primary Care & Cancer, Journal of Cellular Biochemistry (chemoprevention supplements), and Journal of Men’s Health & Gender. He is also a reviewer for Journal of the American Medical Association, Urology, Journal of Urology, New England Journal of Medicine, Annals of Internal Medicine, Cancer, Journal of Clinical Oncology, and European Urology, in addition to several other journals. Dr. Crawford has published nearly 500 articles in peer-reviewed journals as well as 81 articles in nonrefereed journals. He has also written more than 100 book chapters and has given more than 350 presentations at local and regional meetings as well as more than 600 presentations at national and international meetings and seminars. Disclosures |
|
 |
Robert Dreicer, MD Robert Dreicer, MD, FACP, is Chairman of the Department of Solid Tumor Oncology at the Cleveland Clinic and a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. Dr. Dreicer is board certified in internal medicine and medical oncology. His areas of specialization are the management of genitourinary malignancies and the design and conduct of clinical trials in urologic oncology. Dr. Dreicer received his BS degree at Colorado State University and his MS degree at the University of Texas Graduate School of Biomedical Sciences in Houston, Texas. He received his MD from the University of Texas Medical School at Houston. He completed an internal medicine residency at Indiana University in Indianapolis, followed by a medical oncology fellowship at the University of Wisconsin Clinical Cancer Center in Madison, Wisconsin. He joined the Division of Hematology/Oncology at the University of Iowa in 1989, and upon his departure he was a tenured Associate Professor of Medicine and Associate Division Director of Hematology/Oncology. Dr. Dreicer was appointed as a Staff Physician in Hematology/Oncology with a secondary appointment in the Urologic Institute. Dr. Dreicer was appointed Director of the Genitourinary Medical Oncology Program and Associate Director of the Experimental Therapeutics Program in 2000 and Chairman of the Department of Solid Tumor Oncology in January 2006. Dr. Dreicer has published widely in genitourinary oncology, and is the principal investigator of a large number of ongoing studies in genitourinary neoplasms. He is the Chair of the Bladder Subcommittee of the Eastern Cooperative Oncology Group and a Fellow of the American College of Physicians. He has chaired the Department of Defense Prostate Cancer Integration Panel and the Steering Committee of American Society of Clinical Oncology’s 2008 GU Oncology Meeting. He is an Associate Editor of Urology and a member of the editorial boards of the Journal of Clinical Oncology, New England Journal of Medicine’s Journal Watch Hematology/Oncology, and The Journal of Supportive Oncology. Disclosures |
|
 |
Howard M. Sandler, MD, MS Dr. Howard Sandler is currently the Ronald H. Bloom Chair in Cancer Therapeutics and Professor and Chair of the Department of Radiation Dr. Sandler is an expert in prostate and bladder cancer as well as an authority in emerging technologies used to treat cancers. Prior to joining the faculty of Cedar-Sinai’s Samuel Oschin Comprehensive Cancer Institute last year, he served as Newman Family Professor and Senior Associate Chair of Radiation Oncology and Professor of Urology at the University of Michigan. He is a member of several prestigious professional organizations, including the American Society of Therapeutic Radiology and Oncology, the American–Society of Clinical Oncology, the American Urological Association, the Southwest Oncology Group, and the Radiation Therapy Oncology Group. Dr. Sandler has served on more than 50 state and national committees and advisory panels of these and other organizations. He also served as Executive Medical Director and board member for the Radiation Oncology Alliance in Michigan and as a board member for the Northeast Michigan Cancer Center and the Central Michigan Community Hospital Radiation Oncology. He has written more than 160 articles on radiation therapy, primarily prostate cancer-related, in peer-reviewed journals, and has presented at dozens of symposia and meetings around the world. Among his current work, he is the principal investigator on a clinical trial evaluating adjuvant chemotherapy’s role in locally advanced prostate cancer. His trial will be the first to reach its accrual goal. He also has a paper coming out in the Journal of the National Cancer Institute on the role of surrogate markers in prostate cancer. Dr. Sandler is a well-sought-after speaker and writer. In addition to presenting and speaking at more than 100 symposia, workshops, and meetings, Dr. Sandler serves on the editorial boards of the Journal of Clinical Oncology, The Prostate Journal, Oncology.com, and Medscape Hematology-Oncology. He has written more than 130 articles on prostate cancer and radiation therapy in peer-reviewed publications such as Cancer, the International Journal of Radiation Oncology • Biology • Physics, the Journal of Neurosurgery, Radiotherapy and Oncology, the International Journal of Oncology, Neurosurgery, the Journal of the National Cancer Institute, the American Journal of Clinical Oncology, the Journal of Clinical Endocrinology & Metabolism, and the Journal of the American Medical Association (JAMA). Dr. Sandler has co-authored 12 book chapters, is a co-author of the book Brain Tumors, and has served as a manuscript reviewer for the International Journal of Radiation Oncology Biology Physics, the Journal of Neurosurgery, the Cancer Journal from Scientific American, the Journal of Clinical Oncology, Urology, Journal of Urology, The Lancet, JAMA, and Nature Clinical Practice Urology. The recipient of numerous awards, Dr. Sandler was named Teacher-of-the-Year in the Department of Radiation Oncology at the University of Michigan, and has been named in Best Doctors in America and Best Doctors in America: Midwest Region. Disclosures |
|
Disclosure PolicyIt is the policy of ArcMesa Educators that our staff and faculty disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during presentations. Individuals who refuse to disclose will be disqualified from all aspects of this CME activity. ArcMesa Educators has policies in place that will identify and resolve all conflicts of interest prior to this educational activity. |
||
|
||